Neurometabolic profiles of autism spectrum disorder patients with genetic variants in specific neurotransmission and synaptic genes.

Scientists studied brain chemistry in 10 autistic people who had genetic changes affecting brain communication systems. They used brain scans to measure important brain chemicals and found that people with autism who had these genetic changes had lower levels of chemicals needed for brain energy and nerve cell health compared to people without autism. The genetic changes mainly affected systems that help brain cells communicate properly.

This study investigated the relationship between genetic variants in neurotransmitter and synaptic genes and brain metabolism in autism spectrum disorder. Researchers analyzed 12 predicted damaging variants in 12 neurotransmitter/synaptic genes across 10 ASD individuals, with most variants affecting GABA and glutamate pathways. Using proton magnetic resonance spectroscopy (H-MRS), they measured brain neurometabolites and found that ASD patients with these genetic alterations had lower levels of total creatine (tCr) and total N-acetyl aspartate (tNAA) compared to controls. These metabolites are markers of cellular energy production and neuronal health, respectively.

The findings suggest that genetic variants disrupting glutamate or GABA neurotransmitter systems may contribute to metabolic dysfunction in the autistic brain.

Findings suggest potential biomarkers for autism subgroups and highlight the role of neurotransmitter pathway dysfunction in autism. However, clinical utility is limited by small sample size and need for replication in larger studies before informing diagnostic or treatment approaches.

Very small sample size (10 ASD individuals). No information provided about control group characteristics, methodology details, or statistical analyses. Study design unclear. Cannot determine causality between genetic variants and metabolic changes.

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by impaired social interaction, and restricted and repetitive patterns of behavior. ASD presents as a clinical spectrum, with variable levels of severity and multiple co-occurring conditions. The etiology of ASD may involve hundreds of genes and there is evidence that neurotransmitter and synaptic (NS) pathways are implicated. Proton Magnetic Resonance Spectroscopy (H-MRS) has made it possible to study the concentration of brain neurometabolites and compare their levels in the brains of ASD and control individuals.

We integrated genetic variants in NS genes withH-MRS analysis, and identified 12 predicted damaging variants (PDVs) in 12 NS genes in 10 ASD individuals, most mapping to genes involved in Gamma-aminobutyric acid (GABA) and glutamate pathways. Total creatine (tCr) and total N-acetyl aspartate (tNAA), markers of bioenergetics and neuronal metabolism, respectively, were lower in ASD patients with genetic alterations in NS genes compared to a control group without ASD. We conclude that PDVs in NS genes that are important for the regulation of glutamate or involved in GABAergic functions are associated with neurometabolic alterations, and that dysfunction in glutamatergic and/or GABAergic pathways may be implicated as these pathways are linked to the metabolic measures altered in cases.